Is Elevance Health (ELV) a Mispriced Opportunity?

Sound Shore Management, an investment management firm, has published its Q2 2026 investor letter. The letter reveals that Elevance Health, Inc. (NYSE:ELV) was a significant contributor to the fund's performance. Although the fund's flagship funds underperformed the market, the strong rebound in stocks across various sectors, particularly in AI and semiconductors, helped offset the losses.

Elevance Health, a US-based health benefits company, saw a one-month return of 3.64% and a 52-week gain of 28.94%. The firm identified Elevance Health as a noteworthy holding, despite its recent sell-off due to regulatory concerns and weak margins in its Medicaid and Medicare businesses. The stock's price-to-earnings ratio of 13 times was trading below normal, coupled with double-digit earnings growth, indicating that the market might be underestimating the company's potential.

Sound Shore's analysis highlights how Elevance Health's management is focusing on improving margins and reducing administrative overhead through the implementation of AI tools, which have already proven successful in cutting prior authorization denials by nearly 70%. Despite acknowledging Elevance Health's potential, the fund believes that certain AI stocks present greater upside potential with less downside risk.